Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.07 Insider Own0.20% Shs Outstand40.93M Perf Week-31.73%
Market Cap643.83M Forward P/E- EPS next Y-3.43 Insider Trans39.08% Shs Float37.67M Perf Month-28.11%
Income-113.00M PEG- EPS next Q-0.96 Inst Own67.10% Short Float34.29% Perf Quarter-28.40%
Sales15.50M P/S41.54 EPS this Y35.60% Inst Trans1.00% Short Ratio8.35 Perf Half Y-56.40%
Book/sh7.52 P/B2.09 EPS next Y4.20% ROA-37.40% Target Price37.94 Perf Year-59.28%
Cash/sh6.83 P/C2.30 EPS next 5Y9.31% ROE-44.20% 52W Range12.12 - 41.66 Perf YTD-22.78%
Dividend- P/FCF- EPS past 5Y-9.80% ROI-36.30% 52W High-62.24% Beta0.53
Dividend %- Quick Ratio10.40 Sales past 5Y-7.80% Gross Margin- 52W Low29.79% ATR1.80
Employees146 Current Ratio10.40 Sales Q/Q-13.30% Oper. Margin- RSI (14)33.15 Volatility7.00% 8.00%
OptionableYes Debt/Eq0.01 EPS Q/Q-41.70% Profit Margin- Rel Volume0.91 Prev Close15.19
ShortableYes LT Debt/Eq0.01 EarningsNov 06 BMO Payout- Avg Volume1.55M Price15.73
Recom2.40 SMA20-23.38% SMA50-27.24% SMA200-40.06% Volume1,411,636 Change3.55%
28-Oct-14Downgrade Robert W. Baird Outperform → Neutral $53 → $21
01-Aug-14Initiated Oppenheimer Outperform $45
29-Jul-14Upgrade WBB Securities Speculative Buy → Buy $25
22-Apr-14Reiterated Needham Buy $36 → $52
22-Apr-14Reiterated Deutsche Bank Hold $17 → $35
04-Mar-14Reiterated Canaccord Genuity Hold $25 → $27
21-Jan-14Upgrade Needham Hold → Buy $36
26-Nov-13Upgrade WBB Securities Sell → Speculative Buy $9 → $19
13-Nov-13Downgrade Needham Buy → Hold
13-Nov-13Downgrade Deutsche Bank Buy → Hold $71 → $17
12-Nov-13Reiterated FBR Capital Mkt Perform $48 → $20
30-Oct-13Initiated FBR Capital Mkt Perform $48
06-Sep-13Initiated Stifel Buy $51
22-Apr-13Initiated Needham Buy $57
04-Apr-13Initiated Robert W. Baird Outperform $63
03-Apr-13Initiated Robert W. Baird Outperform $63
08-Mar-13Reiterated Burrill Institutional Research Mkt Outperform $54 → $39
26-Nov-12Initiated Burrill Institutional Research Mkt Outperform $54
12-Sep-12Downgrade WBB Securities Hold → Sell $8 → $9
09-Aug-12Initiated WBB Securities Hold $8
28-Oct-14 04:42PM  Twitter and Amgen are big market movers AP
02:10PM  Sarepta Slumps as Eteplirsen NDA Submission Gets Delayed Zacks
10:07AM  Story Stocks from Briefing.com Briefing.com
07:16AM  Sarepta Therapeutics downgraded by Robert W. Baird Briefing.com
06:46AM  Sarepta Slumps: SRPT Plunges 32.5% in Session Zacks
12:56AM  [$$] Sareptas Muscular Dystrophy Drug Suffers Setback at The Wall Street Journal
27-Oct-14 06:06PM  Nasdaq stocks posting largest percentage decreases AP -32.47%
05:46PM  Prosensa pops on Sarepta FDA delay CNBC
04:34PM  S&P 500 trades in a narrow range, up against key technical levels Yahoo Finance Blogs
04:26PM  Merck good medicine? Talking Numbers
03:15PM  Market losers: Sarepta & Tesla CNBC
02:51PM  Sarepta Gets Delayed And The Stock Gets Drilled Benzinga
01:20PM  [$$] Muscular Dystrophy Drug Suffers Setback at The Wall Street Journal
01:15PM  Petrobras Plunges In The Wake Of Brazilian Election Results at TheStreet
12:29PM  3 Stocks, 3 trades: MRK, GRMN & SRPT CNBC
12:27PM  Sarepta Needs FDA Expertise, Stat at Forbes
11:41AM  Sarepta price target slashed by Piper Jaffray at MarketWatch
11:29AM  Sarepta Therapeutics: Don't Catch This Falling Knife at Barrons.com
11:10AM  Sarepta Faces Major Hurdle, and Not From Ebola at 24/7 Wall St.
11:02AM  Sarepta Shares Falls on Duchenne Drug Approval Filing Delay at TheStreet
10:54AM  Sarepta tumbles on new delay for key drug AP
09:47AM  Stocks to Watch: Chiquita, Allergan, Merck at The Wall Street Journal
09:02AM  Valeant may up bid for Allergan...again; Merck mixed results; Apple Pay mobile payment battle Hot Stock Minute
08:32AM  Biotech Stock Crashes After FDA Requires Additional Data For New Drug Application Business Insider
08:00AM  Sarepta Therapeutics Announces Regulatory Update on Eteplirsen Call scheduled for 8:00 am ET today CCBN
07:36AM  Sarepta timeline delayed on muscular dystrophy drug at CNBC
07:20AM  Wall Street struggles to keep up momentum; Merck's profit tops estimates; Apple Pay gets a setback Hot Stock Minute
07:04AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
07:00AM  Sarepta Therapeutics Announces Regulatory Update on Eteplirsen Business Wire
24-Oct-14 02:58PM  Ebola stocks mostly higher after virus confirmed in New York at MarketWatch
10:53AM  Ebola's in New York; is the economy at risk? Yahoo Finance
21-Oct-14 06:45PM  Ebola vaccine could be ready in 3 months: CEO at CNBC
20-Oct-14 10:44AM  Ebola outbreak: Cashing in on a cure Yahoo Finance
06:10AM  A Promising Experimental Ebola Drug Goes Overlooked at BusinessWeek
17-Oct-14 12:00PM  10 biggest financial-market events this week at MarketWatch
10:58AM  Sarepta Therapeutics Shares Up On Ebola Drug Safety Study Benzinga
09:11AM  Carnival slides on Ebola fears; Urban Outfitters tumbles on sales warning; Morgan Stanley blows past estimates Hot Stock Minute
07:39AM  Ahead of the Bell: Sarepta Therapeutics climbs AP
07:27AM  Sarepta Is Surging After Good News For Its Ebola Treatment Business Insider
07:11AM  Stocks soar after volatile week; Housing starts rebounds; Starbucks offering free coffee and more Hot Stock Minute
16-Oct-14 07:38PM  [$$] Sarepta's Ebola Drug Showed No Ill Effects in Study at The Wall Street Journal +6.65%
05:27PM  Sarepta says its Ebola drug has no ill effects at MarketWatch
05:00PM  After-hours buzz: Google, SanDisk, Xilinx & more at CNBC
04:33PM  Sarepta says it sees no side effects from Ebola drug at MarketWatch
04:10PM  Sarepta Therapeutics Announces Publication of Ebola and Marburg Phase I Clinical Study Results in Antimicrobial Agents and Chemotherapy Business Wire
02:05PM  Ebola Stocks on the Move at 24/7 Wall St.
15-Oct-14 04:30PM  Volatility at its finest Yahoo Finance Blogs +10.58%
13-Oct-14 04:30PM  Prosensa Starts Rolling NDA Submission for Drisapersen Zacks
01:06PM  [video] Funding pandemic preparedness at CNBC
01:00PM  [video] CDC: Won't block West African flights at CNBC
12:29PM  Sarepta Drug Could Benefit From Duchenne Muscular Dystrophy Patient Study at TheStreet
10:43AM  Questioning Ebola protocols CNBC
10:43AM  [video] Questioning Ebola protocols at CNBC
10:05AM  US nurses properly trained for Ebola? CNBC
10:05AM  [video] US nurses properly trained for Ebola? at CNBC
10:00AM  Ebola Fears Driving Ebola Stock Winners at 24/7 Wall St.
09:08AM  [video] Ebola: 1st US transmission at CNBC
08:24AM  [video] US hospital preparation in question at CNBC
07:06AM  [video] Ebola care learning curve at CNBC
07:01AM  [video] Health care worker diagnosed with Ebola at CNBC
06:01AM  [video] First US Ebola transmission at CNBC
10-Oct-14 07:50AM  [video] Ebola-killing robot headed to West Africa? at CNBC -5.44%
07:43AM  [video] Ebola zapping robot at CNBC
09-Oct-14 06:30PM  Stock option volumes soar for biotechs with Ebola drugs Reuters
02:32PM  Hazmat Suit Company's Shares Go Parabolic Business Insider
10:10AM  [video] LaGuardia workers strike over Ebola protection: Report at CNBC
07:15AM  [video] Ebola treatments: What we know at CNBC
07:13AM  [video] Fighting Ebola at CNBC
06:08AM  [video] Enhanced Ebola screening at CNBC
08-Oct-14 02:41PM  Ebola-related shares fall after Dallas patient dies at CNBC
12:20PM  Sarepta Therapeutics is not an Ebola play! Yahoo Finance Blogs
12:18PM  [video] Experimental Ebola drugs outlook at CNBC
12:17PM  [video] Questions arise of Dallas Ebola patient's care at CNBC
11:38AM  [video] Outlook for experimental Ebola drugs at CNBC
10:05AM  [video] Ebola: Prepping for worst case scenario at CNBC
08:30AM  Sarepta Therapeutics Announces Presentations at the 19th International Congress of the World Muscle Society Business Wire
07:20AM  [video] Ebola survivor donates blood at CNBC
07-Oct-14 10:46PM  Chimerix's Brincidofovir Given To Dallas, Nebraska Ebola Patients at Forbes
05:28PM  The Ebola drug playbook CNBC
05:28PM  [video] The Ebola drug playbook at CNBC
05:24PM  The Ebola fighters CNBC
05:24PM  [video] The Ebola fighters at CNBC
04:12PM  CDC: Looking at screening process for airlines CNBC
04:12PM  [video] CDC: Looking at screening process for airlines at CNBC
01:57PM  Chimerix Shares Surge After News The Company's Drug Is Being Used To Treat Ebola Patient Business Insider
06-Oct-14 04:27PM  First case of Ebola contracted outside West Africa CNBC -6.31%
04:27PM  [video] First case of Ebola contracted outside West Africa at CNBC
04:09PM  Number of companies fighting Ebola grows, one wins fed OK at MarketWatch
02:08PM  Ebola Sector Shake Out Leaves Chimerix Inc On Top Benzinga
02:06PM  Response to Ebola epidemic in US CNBC
02:06PM  [video] Response to Ebola epidemic in US at CNBC
02:05PM  Reality Sets in for Ebola Drug Hopefuls at 24/7 Wall St.
10:13AM  Dallas patient with Ebola in critical condition CNBC
10:13AM  [video] Dallas patient with Ebola in critical condition at CNBC
09:12AM  Shares Of Biotech Company Chimerix Are Surging After FDA Authorizes Potential Ebola Treatment Business Insider
05-Oct-14 02:16PM  Ugandan Health Worker Dies Of Marburg Virus, Ebola Relative at Forbes
03-Oct-14 12:26PM  It's Been A Huge Day For The Ebola Trade Business Insider +7.72%
11:50AM  Prosensa (RNA) Extends Re-Dosing of Drisapersen into Europe Zacks
10:13AM  Dallas Ebola patient in serious condition CNBC
10:13AM  [video] Dallas Ebola patient in serious condition at CNBC
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.